Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Pan-cancer TROP2 expression and survival in the MONSTAR-SCREEN-2 cohort

Kyosuke Seguchi • 23 Oct 2026
ESMO 2026
General
SCRUM-Japan MONSTAR-SCREEN-2

Kyosuke Seguchi, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses an integrated pan-cancer analysis of TROP2 expression, using RNA sequencing and immunohistochemistry data from the SCRUM-Japan MONSTAR-SCREEN-2 programme (UMIN000043899). Expression varied widely across cancer types and showed only a modest correlation between RNA and protein levels. However, high expression was associated with worse survival in pancreatic ductal adenocarcinoma and urothelial carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kyosuke Seguchi

High CSF1R expression is associated with immune suppression and poor outcomes in gastric cancer
2:11
High CSF1R expression is associated with immune suppression and poor outcomes in gastric cancer
Kyosuke Seguchi • 3 Jul 2026
Could CSF1R expression findings from MONSTAR-SCREEN-2 be used to guide treatment decisions?
1:51
Could CSF1R expression findings from MONSTAR-SCREEN-2 be used to guide treatment decisions?
Kyosuke Seguchi • 3 Jul 2026
Could CSF1R expression be used as a prognostic biomarker in gastric cancer?
1:15
Could CSF1R expression be used as a prognostic biomarker in gastric cancer?
Kyosuke Seguchi • 3 Jul 2026
Single-port surgery advances for mediastinal tumor resection
3:33
Single-port surgery advances for mediastinal tumor resection
Kyosuke Seguchi • 16 Dec 2025

Related Videos

Cost-effectiveness of first-line chemo-immunotherapy in solid tumours
1:32
Cost-effectiveness of first-line chemo-immunotherapy in solid tumours
Jacopo Canzian • 23 Oct 2026
AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals